Skip to main content
. 2020 Jan 31;37(3):1049–1064. doi: 10.1007/s12325-020-01235-y

Fig. 3.

Fig. 3

All-cause mortality of the high dose tigecycline (HDT) regimens compared with controls. HAP hospital-acquired pneumonia, VAP ventilator-associated pneumonia, BSI bloodstream infection, cIAI complicated intra-abdominal infections, CR carbapenem resistant